You are hereKylin Therapeutics' pRNAi technology gets US patent
Kylin Therapeutics' pRNAi technology gets US patent
Kylin Therapeutics, Inc, a leading RNAi company, announced that they have received patent from the US Patent and Trademark Office (US PTO).
“This patent represents new ground recognized in the field of RNA interference,” said Eric Davis, president and CEO of Kylin Therapeutics. “pRNAi is the only self-delivering RNA-based nanoparticle that induces RNA interference to be granted a patent by the US PTO. We are very pleased, not only for our company, but because this type of technology could give physicians a new method for drug delivery in the treatment of diseases including various forms of cancer.”
This issuance follows a notice of allowance made in October of 2009. The patent’s issue date is February 2, 2010. The newly issued patent broadly covers a number of functionalities for Kylin’s lead technology platform, “pRNA”, or “packaging RNA.” These functionalities include receptor binding, ribozyme activity, and RNA-interference. The patent’s principal author is Peixuan Guo, former professor at Purdue University who is now a professor at University of Cincinnati.
Kylin Therapeutics a cutting-edge biotechnology company based in the Purdue Research Park, employs a revolutionary RNA nanoparticle technology platform called “pRNA” to exploit the enormous potential of oligonucleotides for treatment of many common diseases.